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Background Advances in medical genetics herald the
possibility that health and social care services could be
more responsive to the needs arising from a person’s
genotype. This development may be particularly
important for those men and women whose learning
disability (known internationally as intellectual
disability) is linked to a neurodevelopmental condition
of genetic origin.
Method This possibility is tested through interviews with
samples of (i) professional ‘opinion former’ with
nationally recognised clinical and/or academic interests
in learning disabilities and genetics; (ii) representatives
of syndrome organisations prompting the interests of
families where someone has a neurodevelopmental
condition, and parent-members of these same
organisations.
Results The reporting and discussion of the interview
data considers the possibility that notwithstanding the
successes of the social model of disability, the health
and wellbeing of people whose learning disability is
associated with a neurodevelopmental condition could
be better served by a more medicalised approach to
their interests.
Conclusion While a more medicalised approach to this
populations’ disabilities would appear to be beneficial,
so long as it is focused on interventions to improve their
lives rather than catalogues their deficiencies.
Keywords: genetics, health inequalities, healthcare,
neurodevelopment syndromes, social care, intellectual
disability
Introduction
Medical genetics, which relates genetic variation to the
burden of disease and ill health, heralds both
individualized medicine (Evans & Relling 2004) and the
prospect of genetically informed public health policy
(Stewart 2007). However, these revolutionary possibilities
seem to be just that – possibilities (Lander 2011).
Identifying the gene(s) responsible for many common
health conditions (such as schizophrenia) and then
targeting these risks at the individual or population level
is proving difficult because many common illnesses are a
result of complex interactions between multiple genes, as
well as a person’s environment (Ripke et al. 2014). Yet for a
range of conditions associated with either a chromosomal
abnormality, or a mutation in a single gene, this is not the
case. These genetic conditions, often associated with
significant learning disabilities (known internationally as
intellectual disabilities), and frequently referred to as
neurodevelopmental disorders or syndromes, are already
associated with well-documented patterns of ill health and
also particular developmental profiles and propensities to
specific problem behaviours (see O’Brien 2006). Down’s
syndrome, for instance, the most common and familiar
neurodevelopmental syndrome, is due to the inheritance
of an extra copy of chromosome 21 (trisomy 21). Men and
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women with Down’s syndrome are at increased risk of a
number of illnesses and symptoms, including congenital
heart disease, reduced physical activity, weight gain,
depression, sensory impairments and early onset
dementia (http://www.nhs.uk/conditions/downs-
syndrome/pages/introduction.aspx). What is striking is
that these health risks, and those associated with many
other neurodevelopmental disorders of genetic origin,
have very little influence on the design and delivery of
health care (Department of Health, 2013). In other words,
while members of the general population are poised to
benefit from advances in medical genetics, people with
neurodevelopmental disorders of a genetic origin –whose
health risks are much better documented – are not. This
could be seen as yet more evidence that the UK’s
healthcare system is failing to meet the needs of people
with learning disabilities (Heslop et al. 2014). Aiming to
investigate this possibility, we consider whether a more
judicious use of genetic knowledge in the design and
delivery of healthcare and social care services could
improve the health and well-being of those people whose
learning disability has a genetic cause. A provocative
question as it has the potential to reignite past
controversies concerning the eugenics movement of the
late 19th and early 20th centuries, such as illustrated by the
reported case of the Kallikak Family (Goddard 1912),
while also raising the possibility that these populations
might benefit from a re-medicalization of their learning
disabilities, despite the orthodoxies of the social model
(Barnes 2012). Prior to exploring these possibilities
through interviews with key stakeholders, we briefly
introduce how the association between
neurodevelopmental disorders that have a genetic origin
and particular pattern of ill health is understood; review
the current use of genetic knowledge in the provision of
health and social care services; and highlight the
emergence of syndrome-specific support groups
representing the interests of families where a member has
a genetic neurodevelopmental condition. We then report
on original research in which key stakeholders gave their
views on the potential of medical genetics to improve the
health and well-being of these populations. Views that are
then used to discuss whether, and how, a more judicious
use of genetic knowledge might improve the health and
well-being of people whose learning disability is
associatedwith a genetic condition.
Background
Conditions of genetic origin have a characteristic and
identifiable genotype that in many cases provides a
definitive diagnosis when a genetic disorder is
suspected. In some instances, these genetic conditions
will be inherited, carried by a parent (perhaps in a
milder form) and passed down to a proportion of their
children. This is the case with tuberous sclerosis, which
is due to a mutation in either the TSC1 or TSC2 gene,
or, as in the case of fragile X syndrome, a mutation in
the FMR-1 gene that is passed from a mother to her son
who is likely to be more severely affected due to the
mode of inheritance (referred to as X-linked). In other
instances, a genetic condition may be due to a new (de
novo) event in either the sperm or ovum, giving rise to a
genetic ‘abnormality’ (mutation); or to the loss or
duplication of a few genes on a particular chromosome
(referred to as a copy number variant); or, as is the case
in most people with Down’s syndrome, the inheritance
of an extra copy of a whole chromosome. In Prader–
Willi syndrome, for example the genotype is
characterized by the absence (or non-expression) of
what are referred to as ‘imprinted’ genes located on
part of chromosome 15. Where a genetic condition is
due to a de novo event, the chances of a recurrence in
that generation are low, and it is also unlikely that those
with such neurodevelopmental syndromes will,
themselves, go on to have children. It is also the case
that many of the embryos and the subsequent foetuses
affected by these de novo events will not survive
gestation.
The consequence of a person’s genotype is evident
(expressed) in both the form of a physical and also a
behavioural phenotype, the phenotype being the
characteristics associated with that particular genotype
(see Table 1). With respect to a person’s physical
phenotype, this can include distinctive facial features
(associated with many neurodevelopmental syndromes),
characteristic physical and sensory disabilities and, of
particular concern here, specific patterns of ill health.
For example, people with Cornelia de Lange syndrome
exhibit, in addition to a set of characteristic facial
features and low birth weight, a propensity to a
sideways curvature of the spine (known as scoliosis)
and to gastroesophageal reflux in which acid from the
stomach enters and burns the oesophagus causing
extreme pain. In addition to a distinct array of physical
features, researchers have also identified that many of
these disorders of genetic origin are associated with
particular styles of cognitive processing, particular
behavioural characteristics and styles of social
interaction, some of which may meet criteria for autism
spectrum disorder (O’Brien 2002). Known as a
‘behavioural phenotype’, these consequences of a
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person’s genotype can therefore include, amongst
others, a learning disability, autism, repetitive
behaviours, social disinhibited behaviours, abnormal
eating behaviours and high rates of obesity, and self-
injurious behaviour. In addition, some people may also
be at high risk of anxiety disorders and/or psychotic
illnesses. For example, people with velocardiofacial
syndrome (VCFS) may, in addition to a learning
disability, have the developmental profile characteristic
of autism and be at risk for developing schizophrenia.
While some commentators choose to see psychiatric
diagnoses such as schizophrenia, as social constructions
(Rapley 2004), others recognize their utility in enabling
treatment developments, such as medications, that, as
part of a comprehensive treatment programme, have
been shown to have some benefit and to improve the
Table 1 Syndromes and some of the features associated with their physical and behavioural phenotypes1
Syndrome Features
Angelman Genotype: Chromosome 15 (10% unknown genetic cause) de novo mutation; physical phenotype:
gait ataxia, distinct facial features, epileptic seizures; behavioural phenotype: intellectual disability,
speech impairment, inappropriate demeanour including frequent laughter and excitability
Cri du Chat Genotype: Chromosome 5; Mostly de novo mutation, 10% inherited; physical phenotype: cat like cry,
distinct facial features low birth weight and slow growth, scoliosis gastroesophageal reflux;
behavioural phenotype: intellectual disability, slow or incomplete development of motor skills
Cornelia de Lange Genotype: Chromosome 5, 10 or X (35% unknown genetic cause); de novo mutation; physical
phenotype: restricted growth, distinct facial features, gastrointestinal dysfunction, hearing loss;
behavioural phenotype: intellectual disability, autism, self-injury
Down’s Genotype: Chromosome 21 (trisomy 21); de novo occurrence; physical phenotype: poor muscle tone,
distinct facial features, slow physical development, heart problems as well as hearing and eye
problems, underactive thyroid; behavioural phenotype: intellectual disability, early onset dementia
Fragile X Genotype: X chromosome; inherited (if mother is carrier) and de novo mutation; physical phenotype:
distinct facial features, laxity of joints, heart problems; behavioural phenotype: moderate intellectual
disability, mild intellectual disability in females, autism
Prader–Willi Genotype: Chromosome 15; de novo chromosomal abnormality; physical phenotype: hypotonia and
feeding difficulties in early infancy, excessive eating and morbid obesity in adulthood, distinct
facial features short stature, strabismus, scoliosis; behavioural phenotype: intellectual disability,
delayed language development, temper tantrums, psychosis
Rett Genotype: X chromosome; mostly a de novo mutation; physical phenotype: presumed to be lethal in
males, females, developmental stagnation, regression in language and motor skills, episodic apnoea
and/or hyperpnoea, gait ataxia and apraxia, tremor, epileptic seizures, distinctive facial features,
restricted growth, constipation, scoliosis; behavioural phenotype: autistic features, intellectual
disability, repetitive and stereotypic behaviour, panic-like attacks, episodes of inconsolable
crying and screaming
Rubinstein–Taybi Genotype: Chromosome 16 (40–60% unknown genetic cause); de novo mutation; physical phenotype:
distinctive facial features, short stature, propensity towards obesity, eye problems, congenital heart
conditions, renal abnormalities; behavioural phenotype: intellectual disability, intolerance of noise
and crowds, autism, hyperactivity, self-injury, aggression
Tuberous sclerosis Genotype: Chromosome 9 or 16 (15% unknown genetic cause); de novo mutation, 30% inherited;
physical phenotype: benign tumours causing problems in the kidneys, heart, lungs and brain;
behavioural phenotype: intellectual disability
Williams Genotype: Chromosome 7; de novo chromosomal abnormality; physical phenotype: cardiovascular
disease, distinctive facial features, abnormalities in connective tissue the endocrine system and in
growth; behavioural phenotype: intellectual disability, over friendliness and social disinhibition
22q11 deletion Genotype: Chromosome 22; de novo chromosomal abnormality and 7% inherited; physical phenotype:
congenital heart disease, abnormalities in the palate, immune deficiencies, distinctive facial features;
behavioural phenotype: intellectual disability, autism, high incidence of schizophrenia
1The information presented here was gathered from Genetics Home Reference (ghr.nlm.nih.gov) a service of the National Library of
Medicine (NLM) and part of the National Institutes of Health: an agency of the U.S. Department of Health and Human Services.
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well-being of those affected (see Miyamoto et al. 2012).
Before knowledge of a person’s genetic condition – its
genotype and physical and behavioural phenotypes –
can be used to improve a person’s health, it is necessary
to develop interventions using that knowledge.
In the biomedical sciences, researchers have
demonstrated an ability to switch off the excess gene
expression associated with trisomy 21 in Down’s
syndrome, albeit in isolated cells (Sample 2013): a
discovery which raises the possibility that at some point
in future Down’s syndrome might be ‘treatable’ in utero.
No less dramatic is the use of mouse models of specific
genetic syndromes to demonstrate the possibility of
‘switching on’ the MECP2 gene, which is ‘switched off’
in Rett syndrome (Guy et al. 2007); another piece of
research that hints at future ‘cures’. Of possibly more
immediate benefit is the development of
pharmaceuticals that have the potential to shrink the
tumours associated with tuberous sclerosis (Franz et al.
2006). With respect to studies of behavioural, as
opposed to the physical phenotypes, research suggests
that what appear to be ostensibly similar behaviours –
self-injury, temper tantrums and aggression – might
have entirely different causes (Oliver et al. 2013). The
implication here is that, while awareness of a person’s
syndrome does not fully explain his or her behaviour, it
may help to develop interventions targeted at the causal
pathways that lead to those behaviours. A possibility
that would lessen the need to rely upon generic
interventions for something so poorly defined as
‘challenging behaviour’ (Woodcock et al. 2009). This
research also has implications for social care: care
managers who are more aware of a person’s
behavioural phenotype will be more mindful of the
demands falling on family carers and thus their capacity
to cope (Adams et al. 2012).
Successive governments have done much to address
the fact that people with disabilities and rare health
conditions can be disadvantaged in a healthcare system
designed around the needs of the majority population
(Heyman, Swain, and Gillman 2004). For instance, the
Autism Act 2009, the first and only disability-specific
legislation in England and Wales, requires local
authorities and NHS organizations to develop services
that support and meet the needs of those affected by
this condition. Similarly, the Equality Act 2010, should
ensure that the needs of all people with disabilities are
accommodated when receiving health and/or social care
services. Nonetheless, there are consequences of having
a genetic condition that are not so readily remedied by
antidiscrimination legislation. Namely, the sheer rarity
of these conditions mitigates against the possibility of
establishing robust evidence bases when evaluating new
or alternative courses of treatment. In recognition of
this, the government developed a Strategy for Rare
Diseases (Department of Health, 2013) covering
disorders/illnesses that affect five or fewer persons per
10 000 of the population. The strategy has five main
elements that include the following: involving those
affected in implementing the strategy; timely diagnoses
and early intervention for known health problems;
prenatal screening so that prospective parents can make
informed choices when deciding to start a family; the
provision of coordinated and multidisciplinary care; and
researching the most effective approaches when caring
for people affected by a rare disease. The strategy is
unfunded and given that it takes, on average, 17 years
before biomedical research begins to affect clinical
practice, and (Cooksey 2006) it will be a while before
the success (or otherwise) of this strategy can be
assessed. In sharp contrast to this top-down strategy,
there are also a growing number of support groups
representing the interests of families where one or more
members are affected by a rare disease. With respect to
those support groups that specifically represent the
interests of people with neurodevelopmental conditions
of genetic origin, these began forming in the early 70s –
see Table 2 – with the founding of the Down’s
Syndrome Association. Since then their numbers have
grown, partially as a consequence of the knowledge
arising from the Human Genome Project (1990–2003)
and the increasing availability of genetic tests (Peters
et al. 2015). Sometimes characterized as ‘embodied
health movements’ (Brown, Zavestocki et al. 2004),
while some of these groups seek alternative therapies
and treatments, others actively embrace the
medicalization of their condition. Moreover, with the
aim of hastening the development of cures and new
treatments, these groups tend to be very supportive of,
and willing to participate in, medical research (Koay &
Sharp 2013). It has even been suggested that identities
formed around genetic diagnoses could replace more
traditional loyalties based on class and ethnicity (Rose &
Novas 2004). Biological citizenship, grounded in genetic
identities and committed to medical research, poses a
direct challenge to the Disabled People’s Movement
with its commitment to the social model and the view
that disability, irrespective of diagnostic specifics, is
rooted in a shared experience of discrimination and
oppression. Indeed so divergent are these two
perspectives that disability activism, despite the very
obvious political success of the social model
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(Shakespeare 2005), could be bifurcating along these
lines (Hughes 2009).
It is in the context of research that clearly associates
neurodevelopmental disorders of a genetic origin with
particular patterns of ill health, an awareness of
discrimination in the provision of health care and
potential disadvantage in the development of new
treatments, and a grass roots mobilization around
genetics diagnoses, that we are asking: could a more
judicious use of genetic knowledge in the design and
delivery of healthcare and social care services improve
the health and well-being of those people whose
learning disability has a genetic cause? A question that
we sought to address by canvassing the views of
selected stakeholders.
Stakeholder views on the utility of
syndrome-specific knowledge
The stakeholders we interviewed comprised a sample
of: (i) ten persons we are referring to as ‘professionals’
who the authors recognized as having both an interest
in learning disabilities and genetics, and national, if not
international, reputations in this area; (ii) representatives
from eleven syndrome organizations that promote the
interests of those affected by neurodevelopmental
conditions of a genetic origin, and these responders
were identified through their involvement in a small
project funded under the Medical Research Council’s
(MRC) Lifelong Health and Wellbeing initiative; and (iii)
fifty-five parent members, five from each of the eleven
organizations described in Table 2. The syndrome
organization representatives identified these parent
members. The interviews were semi-structured, the
major themes addressed in the interviews being
determined by our research interests and the fact that
the experiences and expertise of these three groups of
respondents are significantly different. The interviews
with the ‘professionals’ addressed the practical utility of
using syndrome-specific knowledge to improve the
healthcare and social care services received by people
whose neurodevelopmental syndrome has a genetic
origin; the representatives from the syndrome
organizations were asked about the aims of their
respective organizations and their efforts to promote the
interests of their members; while the interviews with the
parent members of these organizations focused on their
experiences of raising a child, and in some cases, a now
adult child with a neurodevelopmental condition.
However, in order to develop a lively discussion where



















Education & Research Trust
1993 300–350 6 1600 21
Cri du Chat 1989 80 5 1300 6
The Cornelia de Lange Foundation 1988 360–450 5 1300 32
Down’s Syndrome Association 1970 20 000 313 79 000 25
The Fragile X Society 1990 1850 100 25 300 7
Prader–Willi Syndrome Association UK 1982 800 5 1200 66
Rett UK 1985 695 25 6300 11
Rubinstein–Taybi Syndrome UK
Support Group
1986 173 2 500 34
Tuberous Sclerosis Association 1977 727 43 10 900 7
Williams Syndrome Foundation 1980 1000 13 3200 32
Max Appeal! (22q11.2 deletion syndrome
support group)
2000 425 63 15 800 3
Prevalence of all eleven syndromes and
estimate of UK population affected
– – 479 146 563 –
1The membership records of some of these organizations were not always up to date.
2Population of UK in 2012 was 63.32 million rounded up to the nearest hundred.
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respondents could develop their own lines of thinking
and reasoning, the interviewer (Merel Pannebakker, the
second author) was encouraged to adopt a lively
conversational style (Holstein & Gubrium 1997). All the
interviews, in order to keep costs to a minimum, were
conducted over the telephone and answers were
recorded contemporaneously by hand, with only key
phrases or expressions preserved verbatim. The
interviews, which lasted between 45 and 90 min, were
then examined for content (Cirourel 1964), with
emergent themes identified and coded. As it was our
intention only to document arguments for-and-against a
more judicious use of genetic knowledge in the design
and delivery of health and social care (not analyse
respondents’ construction of their subjective
experiences), no quotations from the interview data are
presented. Ethical approval for the project was sought
from NRES (www.nres.nhs.uk/) who classified the
project as a service evaluation. The views of the
‘professionals’ are reported first, followed by those of
the representatives of the syndrome organization, and
finally, those of the parent members of these
organizations.
Professionals
The sample of ten professionals comprised three
persons with an in-depth knowledge of one or more
neurodevelopmental syndromes associated with
learning disabilities (two psychiatrists and a
psychologist) and six generalists with a clinical and/or
academic interest in the genetic basis of learning
disabilities but lacking specialist knowledge of any one
neurodevelopmental syndrome (two clinical geneticists,
a psychiatrist and one each of the following: a
psychologist, a nurse with learning disability and a
disability studies scholar).
All but one of the ‘professionals’ endorsed the idea
that knowledge of a person’s neurodevelopmental
syndrome – over and above any general understanding
of his or her learning disability – could, and should,
play a decisive role in the provision of health care. This
view was based on the belief that with knowledge of a
patient’s neurodevelopmental syndrome, and in
particular its physical phenotype, healthcare
practitioners could actively look for symptoms of
syndrome-related illnesses, rather than merely respond
to signs of ill health. Adopting such an approach, it was
asserted, would be especially beneficial where patients,
because of communication difficulties, were unable to
give reliable reports of their symptoms. In a similar
vein, a number of respondents suggested that annual
health checks, which many people with a learning
disability are entitled to (Michael 2008), should be
specially adapted so as to ensure they include those
health risks that are related to the person’s genetic
syndrome. One respondent went further, suggesting
that family carers and direct support staff (DSS)
proactively make regular appointments with their
general practitioners (GPs) for the purpose of reviewing
syndrome-related health risks, rather than waiting until
the person concerned showed signs of ill health. That
said, these ‘opinion informers’ were well aware that
many GPs, as well as healthcare practitioners in
secondary services, can be reluctant to engage with
patients’ genetic conditions. A claim that was
substantiated by observing that when parents proffered
information sheets concerning a son or daughter’s
condition, these were routinely ignored. Although
critical of this, these professionals understood why this
might be occurring, suggesting, for example that
clinicians may have doubts about the validity of the
information provided or that a patient’s genetic
syndrome may not be relevant to the health condition
being treated. When asked how best to improve
clinicians’ knowledge of patients’ genetic syndromes,
many of these respondents had little to suggest other
than more or better training and education. This
suggestion often came with a caveat that, as many of
these syndromes are extremely rare, a clinician may
never meet a patient with one of these
neurodevelopmental disorders. A more imaginative
proposal was that clinicians received training in the
principles of caring for patients with rare genetic
conditions. The fact that there are variations in the
health needs of people with the same
neurodevelopmental condition was not seen by these
respondents as undermining the perceived clinical value
of syndrome-specific knowledge except, that is for the
two respondents, otherwise committed to the clinical
utility of knowing a person’s physical phenotype, who
questioned the clinical benefits of knowing a person’s
behavioural phenotype. These two respondents were of
the view that behavioural phenotypes lacked specificity
as the same behaviours can occur in more than one
syndrome (Hodapp & Dykens 2004). Only one
‘professional’ raised the prospect of syndrome-specific
medication, highlighting the treatment of brain tumours
in tuberous sclerosis (Franz et al. 2006), a breakthrough
that this respondent saw as likely to extend people’s
lives and dramatically improve their well-being. That
only one respondent drew attention to the advance in
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syndrome-specific medication may reflect our small
sample size but also it may signal the belief that
neurodevelopmental conditions are essentially incurable.
The one ‘professional’ who was critical of health care
adopting a syndrome-specific focus held the view that
improving health care for these patients depended upon
improving health care of all patients with learning
disabilities, not just those with a genetic syndrome. In
the opinion of this respondent, knowledge of patients’
neurodevelopmental conditions could never play a
decisive role in the provision of health care because the
rarity of these syndromes precluded the development
and implementation of the necessary clinical expertise.
Far more important for this respondent – who
acknowledged the existence of syndrome-specific
patterns of ill health – was ensuring that patients
received person-centred care and treatment. This, it was
believed, would ensure that people with a
neurodevelopmental condition received health care that
was appropriate to both their syndrome-specific health
conditions as well as those health problems they might
share with the general population, including people
whose learning disability does not have a genetic origin.
Amongst those respondents who otherwise advocated a
more syndrome-specific focus to health care, some
shared concerns similar to those of this respondent.
These respondents mentioned, for instance, that for at
least a third of all people with a learning disability,
there was no identifiable cause (genetic or otherwise);
that an emphasis on people’s physical and behavioural
phenotypes might lead to them being seen as ‘ticking
time-bombs of ill health’; and that developments in
prenatal screening might lead to an unwelcome increase
in the number of pregnancies being terminated.
Commenting on the utility of syndrome-specific
knowledge in the provision of social care services, two
respondents thought it had no place. In their view,
social care was primarily concerned with daily life and
community participation and, as such, it should be
person centred. Focusing on people’s medical
conditions, they thought, would lead to a kind of
‘genetic fatalism’ thereby lowering expectations of what
a person could achieve. In sharp contrast, the other
eight respondents emphatically believed that providers
of social care should take far more interest in people’s
genetic conditions. This opinion rested not just on the
increasing integration of health and social care
(Department of Health, 2011), but on the fact that a
significant amount of health care – identifying
symptoms and following treatment plans – already
occurs within social care settings. In the judgement of
these respondents, good health care depends on direct
support staff being aware of a client’s syndrome-specific
health risks. One of these respondents was of the
opinion that it was time to acknowledge that people
labelled as having a ‘learning disability’ comprise a
diverse population and that being person centred means
being aware of a person’s genetic syndrome and his or
her syndrome-specific health risks. Allied to this,
another respondent observed that the social care needs
of family carers also vary significantly depending on the
neurodevelopmental condition affecting a son or
daughter, a point that was illustrated by the story of a
child with Cornelia de Lange syndrome whose parents
became the subjects of a safeguarding inquiry. The boy’s
care manager failed to appreciate that signs of
malnourishment and severe bruising could be a
consequence of chronic reflux and self-injurious
behaviour both features of the physical and behavioural
phenotype for people with Cornelia de Lange
syndrome. This same respondent, a strong advocate for
the relevance of behavioural phenotypes in social care,
also suggested that when social service departments are
promoting a person’s social inclusion they often
overlook syndrome-specific risk. For example, for
people with Angelman syndrome, the possibility of
forming inappropriate relationships due to a desire for
social attention (Oliver et al. 2013); in Prader–Willi
syndrome, the risk of overeating and life-threatening
obesity (Holland et al. 2003); and in the case of people
with autism, which is associated with some
neurodevelopmental syndromes, an aversion to social
encounters.
To sum up: the majority of ‘professionals’ did not
foresee breakthroughs in biomedical research as the
main route to improvements in the health and well-
being of these populations. Rather, they saw
institutional reforms – better training for clinicians in
the principles of treating people with rare syndromes,
the inclusion of syndrome-specific health risks in annual
health checks and ensuring that direct support staff and
care managers are aware of syndrome-specific health
risks – as the factors most likely lead to improvements
in people’s lives. In other words, these respondents saw
the medicalization of people’s learning disability –
knowing their genotypes and associated physical and
behavioural phenotypes – as crucial to improving their
health and well-being. A minority held a contrary view
emphasizing instead the importance of adopting a
person-centred approach to meeting people’s healthcare
needs and they were concerned that, by defining people
by their syndrome-specific disabilities and health
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problems, this would lead inevitably to genetic fatalism
and pessimism.
Syndrome organizations’ representatives
The respondents representing the eleven syndrome
organizations were, in all but one case, parents of a
child with a neurodevelopmental condition.
Interestingly, these organizations counted their
membership in terms of households – one or more
parents and a child with the ‘qualifying’ syndrome –
rather than in terms of individuals. Unsurprisingly, the
representatives saw their respective memberships as
different from the wider population of people with a
learning disability. These differences they described in
terms of phenotypical differences in facial features,
physical and sensory disabilities, and known health
risks. However, these respondents were also keen to
stress the heterogeneity of their memberships. They
noted, for instance, variations in the severity of people’s
learning disabilities, the degree to which people could
be affected by comorbid physical and sensory
impairments and differences in which people with the
same syndrome were able to participate in society.
Nonetheless, having the same genetic identity is the
defining characteristic of those in these support groups.
The significance of this identity, moreover, was
apparent in the kinds of organizations these support
groups chose to be affiliated with: only two of the
eleven representatives reported affiliations with national
UK learning disability charities, while all eleven
representatives described affiliations to organizations
representing people with specific medical conditions
(such as epilepsy), rare diseases and umbrella groups
for people with genetic conditions. Moreover, many
representatives reported links to similar syndrome-
specific groups in other anglophone countries.
When asked about the aims of their organizations, all
the representatives answered in broadly similar terms
mentioning the offering of advice and information to
families, providing social opportunities so that these
families could meet and encourage each other and
supporting biomedical research that might benefit their
memberships. Of these activities, providing parents with
information concerning a child’s genetic condition was
seen as particularly important. This information
provided parents with some indication of the life they
and their son or daughter was likely to lead, while also
equipping parents with such information as might be
useful when in conflict with health and social care
services. The support these organizations offered to
researchers was predominantly assistance with
recruiting research participants and such research came
through close ties to individual academics. These
academics would often sit on support group’s scientific
advisory panels and speak at annual meetings on the
latest research findings.
With respect to the provision of health care, these
representatives were, in the main, critical of all
healthcare practitioners except paediatricians, who were
seen as better informed and more willing to engage
with a child’s genetic condition. In some cases, this
criticism of healthcare practitioners was tempered by an
awareness that these clinicians, because of the rarity of
the syndrome, did not regularly meet patients with
these conditions. Nonetheless, parents were described as
extremely distressed when a healthcare practitioner
displayed a reluctance to learn about their son or
daughter’s genetic condition. As a means of addressing
this problem, two of the syndrome organization
representatives proposed the introduction of syndrome-
specific clinics. These clinics, they envisaged, would be
multidisciplinary, convene two or three times a year
and held in different parts of the country thus enabling
parents to access an integrated health service where all
of their child’s physical and mental health problems
could be addressed by clinicians with the relevant
expertise. None of the representatives referred to the
introduction of annual health checks, let alone the
possibility that these might be extended to include those
health conditions specific to a person’s genetic
syndrome. Three respondents did, however, mention
the development of pharmacological treatments for
some syndrome-related health conditions, but for two of
these respondents, this was thought to be only a remote
possibility. As such, these respondents did not
anticipate any kind of medical breakthroughs that
would lead to dramatic improvements in people’s
health. Rather, they were of the opinion that
improvements in people’s health would come about by
ensuring clinicians were better informed about people’s
syndrome-specific health risks. With respect to social
care, these representatives were less clear about the role
that genetic knowledge might play, stressing instead the
importance of recognizing a person’s potential rather
than the disabling effects of his or her genetic condition.
What most respondents considered important was that
services enabled people to participate in society and
access their local communities, and as such, these
interviewees did not expect direct support staff to be
particularly knowledgeable of a person’s genetic
condition. Where there was criticism, this was
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specifically aimed at those care managers who sought to
promote the autonomy of service users, irrespective of
parents’ worries about a child’s syndrome-specific
vulnerabilities. These vulnerabilities included the risk of
overeating in people with Prader–Willi syndrome, and
the social disinhibition, anxieties and social phobias that
are associated, respectively, with Angelman syndrome,
Williams syndrome and fragile X syndrome. Care
managers were also criticized for failing to appreciate
just how demanding it could be caring for a son or
daughter with a neurodevelopmental disorder. In
summary, these syndrome organizations were strongly
committed to their members’ genetic identities
recognizing, however, that their affected members
varied in their physical and behavioural phenotypes.
Genetic identities were seen as paramount when
accessing health services, but here again, the route for
improving people’s health and well-being was thought
to lie in institutional reform – clinicians being more
willing to engage with people’s genetic conditions and
the introduction of multidisciplinary clinics – rather
than the discovery of a cure or a revolutionary new
treatment. When accessing social services, there was less
emphasis on the importance of people’s genetic
identities but there was, nonetheless, criticism of a care
manager who failed to appreciate parents’ syndrome-
specific concerns.
Parent members
The sample of parent members of these syndrome
organizations included 44 parents of younger children
(up to the age of 18) and 11 parents of adult children
(aged 18 years and over). By comparing the views of
these two different sets of parents, our interview data
reveals how the significance of a son or daughter’s
genetic condition can change over time. All the parents
we spoke to reported extensive contact with clinical
services, especially hospital paediatrics, when it became
apparent that their newborn child was visibly disabled,
ill and/or failing to thrive. Receiving a diagnosis –
whether by clinical assessment or by genetic test – was,
for these parents, very important. It gave them a
credible explanation for their child’s health conditions
and developmental delays. Moreover, some parents
described how receiving this diagnosis reassured them,
in some unspecified way, that they were not responsible
for their child’s condition, even in the case of inherited
conditions. Armed with a diagnosis, as well as an
awareness of their son’s or daughter’s health problems,
these parents described how they then set about
learning all they could about their child’s
neurodevelopmental condition, including making
contact with the relevant syndrome organization.
Parents told us that they really valued these syndrome
organizations as they provide opportunities via
websites, newsletters, social activities and annual
meetings to learn more about their child’s genetic
condition, the realities of parenting such a child and
how to get the best from health and social care services.
Despite having a highly medicalized view of their son
or daughter’s plight, these parents also stressed their
child’s unique personality and that he or she did not
necessarily possess all the traits associated with that
particular syndrome. Parents were highly critical of
healthcare professionals who were unwilling to learn
about their son or daughter’s genetic condition.
However, it was apparent from the interviews with the
parents of older children that they were less concerned
with their children’s health problems (so long as they
were not acute) as these were at least familiar and they
had had many years’ experience in responding to them.
These parents were concerned about the lack of
opportunities for their adult sons and daughters to
acquire some degree of independence and possibly
move out of the family home. The most significant
barriers in achieving greater social inclusion and
independence, as identified by these parents, were
mental health problems. These were seen as severely
limiting opportunities to use public transport and secure
paid employment. The debilitating effects of mental
health problems were keenly felt by those parents who
believed that, but for these problems, their adult
children could achieve far more. Yet at the same time,
these parents were highly critical of those care
managers who, as they saw it, underestimated the
extent to which a son or daughter’s learning disability
and/or their mental health problems made greater
independence either unrealistic or very risky. These
parents, with few exceptions, did not expect care
managers to be particularly knowledgeable about a son
or daughter’s genetic condition, except where a lack of
understanding was thought to put their adult child at
risk. This was particularly so for the mothers of three
older children with either fragile X, Williams or Prader–
Willi syndrome. These mothers complained that the care
managers, with responsibility for their adult children,
had little comprehension of how these syndromes might
impact on a person’s life.
When asked about the kind of future they saw for
their son or daughter, all the parents we spoke to
wanted to see a world in which their children were
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accepted and, despite their disabilities, had
opportunities to participate in society. A minority hoped
for a medical breakthrough, but these hopes were
largely confined to the treatment of specific health
conditions, not a global cure for either their syndrome
or the learning disability associated with it. The only
exceptions to this were the five mothers of daughters
with Rett syndrome; they had hopes of a cure following
recent reports in the British media of a possible cure
(see BBC News, 2007).
In summary: these parents were committed in their
belief as to the benefits that may come from
medicalization of their children’s disabilities. In this
respect, receiving a genetic diagnosis had an existential
significance for these parents: it is central to their
attempts to understanding both their own and their
child’s predicament and, as such, they expect both
clinicians and care managers to take it seriously.
However, as their children reach adulthood, when they
might be expected to attain independence, the practical
implications of that diagnosis declines and these parents
become more concerned about the impact that mental
health problems could have on opportunities for social
inclusion.
Discussion
This small-scale study had limitations, most notably,
the absence of views from people with a
neurodevelopmental syndrome, and the fact that we
did not canvas the opinions of parents who had not
joined a syndrome support group. Our recruitment of
respondents was also somewhat idiosyncratic and
could well have biased our findings. In identifying
‘professionals’, we traded upon our own knowledge of
those who we thought could offer well-informed
opinions; while the choice of family members
interviewed was entirely under the control of the
syndrome organization representatives. In addition, the
fact that respondents’ answers were recorded by hand
means that we will have lost some of the subtlety of
their opinions. Nevertheless, the data collected
provides a unique set of materials with which to
reflect upon whether a more judicious use of genetic
knowledge in the design and delivery of healthcare
and social care services could improve the health and
well-being of people whose learning disability has a
genetic cause.
Given the sample of stakeholders interviewed, it is
perhaps not surprising that an overwhelming majority
favoured giving genetic knowledge a more prominent
role in the provision of services. This point of view,
however, has its subtleties. The benefits of genetics
research were not thought to lie in the development of
new treatments, but in institutional reforms: training in
the principles of supporting patients with rare
conditions; the inclusion of syndrome-specific health
risks in annual health checks; the introduction of
syndrome-specific multidisciplinary clinics; and
ensuring that direct support staff receive training in the
syndrome-specific health risks of the people they
support. The last of these reforms draws attention to the
fact that a significant proportion of this population’s
health care is provided in social care settings by direct
support staff with little or no clinical training.
Complaints that health care practitioners can be
unwilling to engage with patient’s genetic syndromes
may be harder to address, as these complaints signal
deficiencies in the attitudes of clinicians, rather than
how services are organized and delivered. Nevertheless,
if healthcare practitioners were more sensitive to the
existential significance that a son or daughter’s genetic
diagnosis has for these parents, they might be more
willing to learn about it as a means for developing and
sustaining a clinical relationship with these parents. It is
difficult to see how reforms along these lines could be
anything but beneficial, and in full accord with the
government’s aim of improving health care for people
with rare diseases (Department of Health, 2013). When
considering why the design and delivery of health care
is not more informed by the diagnosis of these
conditions, we should perhaps reflect on the fact that
‘learning disabilities’, as part of a medical speciality, has
lacked a significant institutional base since the closure of
the long-stay hospitals.
Social care is a particular worry for parents with adult
children. This is not, in the main, because care
managers fail to recognize the syndrome-specific needs
of their children – although this is a concern for some
parents – rather, these parents are distressed about the
detrimental impact their son or daughter’s mental
health problems have on opportunities for social
inclusion and greater independence. As such, it is
revealing to note that in England neither the
Government policy paper Valuing People nor its
subsequent follow-up, Valuing People Now (Department
of Health, 2001, 2009), address, in any detail, the
support needs of people with mental health and/or
behavioural problems, whether they have a
neurodevelopmental syndrome or not. It remains to be
seen whether studies of behavioural phenotypes will
lead to more effective interventions, both
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pharmacological and non-pharmacological, that might
lessen the incidence of so-called ‘challenging behaviour’
(Woodcock et al. 2009; Oliver et al. 2013) and provide
those affected with more opportunities to participate in
society.
It is widely believed that when people’s disabilities
are seen as medical problems, this invariably means
focusing on their deficits and what they cannot do.
This argument is at the core of the social model of
disability and its goal of social reform (Oliver 1990).
Yet the parents we spoke to actively embraced a
medical understanding of their children’s
predicaments, saw an understanding of their child’s
genotype and associated phenotype as essential to
promoting their interests and had joined support
groups in which membership is defined through a
genetic identity. These parents, as well as the
overwhelming majority of ‘professionals’, saw
medicalization as essential to promoting the health and
well-being of these populations. In other words, there
is potentially more to a medical diagnosis than the
perceived denigration of a person with a disability; it
can become a route to a better understanding of what
is deemed a medical condition and to campaigning for
more appropriate health care. Nonetheless, these
parents, and the representatives from the eleven
syndrome organizations, also sought to counter the
potentially homogenizing effects of a diagnostic label
by emphasizing the uniqueness of each child,
including how their son or daughter differed from the
physical and behavioural phenotypes associated with
their chromosomal condition. Foregrounding a genetic
identity flies in the face of the People First Movement
and its campaigning slogan to ‘label jars not people’
(http://www.peoplefirst.org). It is possible, however,
that a genetic label, especially at a time when genetic
science is at the forefront of public consciousness,
provides a more coherent basis for formulating a
campaigning identity than the designation ‘learning
disability’, which can encompasses a hugely diverse
population. It might also be the case that a genetic
identity is less stigmatizing, as the extent and nature
of a person’s disabilities are not directly revealed, only
that the person concerned probably has some special
needs. Moreover, given the concerns that these parents
have for the health of their children when newborn, it
is entirely understandable that they have adopted, as
other researchers have reported (see McLaughlin et al.
2008) a highly medicalized understanding. The
increasing availability of prenatal genetic tests raises
concerns over the message that these tests convey about
the value of life with a disability (Saxton 2000), and
the choices of parents who decide not to terminate a
pregnancy where an unborn child is identified as
having a neurodevelopmental syndrome (Reinders
2000). But should these issues, which are tied to
complex arguments over genetic testing and
termination of pregnancies (c.f. Shakespeare 2013), be
allowed to affect the health care received by people
who have already been born? The minority of
‘professionals’, who expressed concerns about focusing
on people’s genetic syndromes, whether in the context
of health care or social care, raised two related issues.
Namely, that care and treatment should be person
centred and that people should not be defined by their
health risks. People with learning disabilities have,
historically, been defined almost exclusively by their
perceived deficiencies; deficits that, in the climate of
the times, the medical profession catalogued, measured
and used to justify incarceration in long-stay hospitals
(Rolph et al. 2005). There is justifiable concern,
therefore, that a re-medicalization of people’s learning
disabilities by focusing on the genetic causes of some
people’s disabilities could renew old practices and
prejudices. But is this really possible, when the
institutional basis for this, the long-stay hospitals, are
long gone, and national policies and legislation are
clearly aimed at promoting equal rights, access and
opportunities (see Valuing People Now 2009 and the
Care Act 2014)? Moreover, how can people with
disabilities, and in particularly those whose disabilities
have a genetic origin, enjoy ‘the highest attainable
standard of health’ (United Nations, 2006) if clinicians
and DSS do not give due regard to their syndrome-
specific health risks? Surely, being cognizant of a
person’s genotype and health-related risks is as much
a part of providing person-centred care and support,
as respecting a person’s will and preference? In other
words, it might be time for an embodied
understanding of people’s impairments: one which
recognizes the significance of both embodied health
risks and the need for institutional reform to counter
discrimination (Bill Hughes & Paterson 1997).
In sum, the case for a more judicious use of genetic
knowledge in the design and delivery of healthcare and
social care services for people whose learning disability
has a genetic cause seems overwhelming. Introducing
syndrome-specific risks into annual health checks and
care plans would involve negligible cost, while having
the potential to save money where this resulted in the
early detection and treatment of ill-health.
Multidisciplinary clinics convened two or three times a
© 2016 The Authors. Journal of Applied Research in Intellectual Disabilities Published by John Wiley & Sons Ltd.
Journal of Applied Research in Intellectual Disabilities 11
year would enable parents, and also social care
providers, to access integrated services where a
person’s physical and mental health problems could be
addressed by clinicians with the relevant expertise.
Such clinics could also provide an opportunity for
closer collaborations between research active clinicians,
syndrome-specific support groups and parents. Again,
where these clinics enable the early detection of ill-
health, and lead to fruitful research partnerships, these
might offset the necessary costs. With respect to raising
awareness of syndrome-specific health risk in both
mainstream services (GP surgeries and general
hospitals) and specialist community learning disability
services, an NHS branded website that provided
relevant information might be very useful. And again
would not be particularly costly. The biggest barrier to
any of these changes, however, is likely to be the small
number of persons affected by any one syndrome.
Although, with respect to the 11 syndromes discussed
here, their combined prevalence is 479 per 250 000 of
the population (see Table 2). The continued advance in
genetic research, and the growing maturity of these
syndrome support organisations, is likely to generate
growing pressure for greater recognition of people’s
genetic syndromes in both health and social care
services: biological citizenship. It may also be the case
that the era when people with very different
impairments mobilize under a shared experience of
discrimination and oppression is coming to an end. We
say this, because formal equality is now guaranteed
under law, and the vast majority of people with
impairments do not actually identify as disabled
(Shakespeare 2013), while a significant proportion of
people do seem willing to be identified through their
medical diagnoses.
Conclusion
The health and well-being of those people whose
learning disabilities are associated with conditions of
genetic origin could be improved through a number of
low-tech reforms that give greater prominence to their
syndrome-specific health risks. Mental health and
behavioural problems are more intractable; yet, research
into behavioural phenotypes holds out the possibility of
pharmacological and non-pharmacological interventions
that could enhance opportunities for participating in
society. In summary, a medicalization of these
populations’ learning disabilities would appear to be
beneficial to the extent it is focused on interventions
that potentially improve people’s lives rather than
catalogues their deficiencies. As such, the association at
the centre of the social model of disability, which
associates the medicalization of people’s disabilities
with social oppression, has to be seriously scrutinized.
Otherwise, there is the distinct possibility that many
people whose learning disabilities are associated with a
condition of genetic origin will fail to benefit from
advances in medical genetics.
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